Cephalon, Teva Settle Patent Dispute Over Provigil

Law360, New York (December 11, 2005, 12:00 AM EST) -- Cephalon Inc. and Israeli generic-drug maker Teva Pharmaceutical Industries Ltd. have struck a deal to put an end to their patent disputes involving Cephalon's narcolepsy drug Provigil, the two companies said.

Under the terms of the settlement, Cephalon will grant Teva the rights to market its generic version of Provigil in the U.S. up to three years before Cephalon's patent expires in October 2014, or as early as October 2011, the companies said.

In return, Teva will pay for royalties to Cephalon generated from any generic-drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.